You are here: Industry Insights > ADC

News List

Eisai, BMS Enter Global Anticancer ADC Alliance contractpharma
June 21, 2021
?Eisai Co., Ltd. and Bristol-Myers Squibb Co. entered an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC).
VERAXA and Quadira Enter ADC Development Partnership contractpharma
June 16, 2021
?VERAXA Biotech GmbH (former Velabs Therapeutics GmbH), an ADC engineering and functional antibody screening company, has entered into a partnership with Quadira Biosciences AG of Zug, Switzerland, to develop a suite of novel ADCs for the treatment of ...
WuXi XDC and LegoChem Ink ADC Agreement contractpharma
June 15, 2021
WuXi XDC, a global CDMO providing end-to-end bioconjugates services, and LegoChem Biosciences (LCB), signed a Memorandum of Understanding (MOU) for a partnership in development and manufacturing of antibody-drug conjugates (ADCs).
VERAXA Biotech and Quadira Biosciences Enter Partnership on ADC Development b3cnewswire
June 15, 2021
VERAXA Biotech GmbH (former Velabs Therapeutics GmbH), announced today that it has entered into a partnership agreement with Quadira Biosciences AG, Zug, Switzerland， to jointly develop a suite of novel ADCs for the treatment of oncological conditions.
Iksuda Therapeutics raises $47m to progress ADC pipeline pharmatimes
June 08, 2021
Newcastle, UK-headquartered Iksuda Therapeutics has announced the closing of a $47m (￡34m) financing round, with the funds to be used to support the advancement of its lead antibody drug conjugate (ADC) assets.
Pandemic inevitably slows pharma M&A activity but appetite for deals remains cphi-online
June 07, 2021
The initial outbreak of the COVID-19 pandemic delayed merger and acquisitions in the pharma sector, but evidence points to an uptick in activity because the rationale for sealing deals hasn’t changed
Avid Bioservices to Manufacture Zynlonta for ADC Therapeutics contractpharma
May 26, 2021
Avid Bioservices Inc., a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing development and manufacturing services to biotechnology and pharmaceutical companies, will serve as ...
Zydus launches Ujvira (trastuzumab emtansine) for breast cancer treatment expresspharma
May 25, 2021
Zydus Cadila launched Trastuzumab Emtansine, an antibody-drug conjugate (ADC) biosimilar and a drug for treating both early and advanced HER2 positive breast cancer, under the brand name ‘Ujvira’.
Sterling Pharma Appoints Stewart Mitchell as New Site Head contractpharma
May 25, 2021
Sterling Pharma Solutions, a global CDMO, has appointed Stewart Mitchell as site head of its new antibody-drug conjugate (ADC) facility in Deeside, UK. Dr. Mitchell will lead the Deeside facility, and report to Kevin Cook ...
GeneQuantum Raises Hundreds of Millions RMB in Series C Funding prnasia
May 19, 2021
GeneQuantum Healthcare (Suzhou) Co., Ltd. announced the completion of Series C fund raising of several hundreds of millions RMB.